Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6

Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6

BackgroundTocilizumab (TCZ), an interleukin-6 receptor antibody, has previously been used for treating patients with the coronavirus disease 2019 (COVID-19), but there is a lack of data regarding the administration timing of TCZ.ObjectivesThis study aimed to evaluate the timing and efficacy of TCZ i...

Full description

Bibliographic Details
Main Authors: Pan Li, Zhengmao Lu, Qiang Li, Zhenmeng Wang, Yan Guo, Chen Cai, Shengyun Wang, Peng Liu, Xiaoping Su, Yi Huang, Yuchao Dong, Wenjuan Qiu, Yueming Ling, Lonny Yarmus, Fengming Luo, Li Zeng, Chong Bai, Wei Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Molecular Biosciences
Subjects:
cytokine storm
interleukin-6
SARS-CoV-2
tocilizumab (TCZ)
coronavirus – COVID-19
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2021.651662/full

Internet

https://www.frontiersin.org/articles/10.3389/fmolb.2021.651662/full

Similar Items